What FDA Adverse Event Reports Reveal About Tirzepatide Safety in the Real World | Research

The takeaway

Analysis of nearly 2 million FDA adverse event reports found 46 tirzepatide-associated reactions, confirming expected GI side effects while also flagging unexpected signals like dosing errors and injection site bleeding.

46 adverse reactions identified
From nearly 2 million FDA reports in the first 18 months of tirzepatide use, researchers found both expected and unexpected safety signals using four statistical detection methods

What the researchers found

Analysis of the FDA's adverse event database (FAERS) identified 46 tirzepatide-associated adverse drug reactions across 8 organ system classes from over 1.9 million reports between Q2 2022 and Q3 2023.

Many identified adverse events were expected and consistent with drug labeling, including gastroesophageal reflux disease, dyspepsia, and vomiting. However, the analysis also uncovered unexpected signals including incorrect dose administered, injection site hemorrhage, and paradoxically increased appetite. These unexpected signals were associated with injury/procedural complications, general disorders, and metabolic/nutritional disturbances.

Why it matters

Tirzepatide (Mounjaro/Zepbound) has rapidly become one of the most prescribed medications in the world, but clinical trials only capture a limited picture of safety. Real-world adverse event data from millions of reports provides a broader view of what actually happens when diverse patient populations use the drug outside of controlled trial settings. Identifying unexpected signals like dosing errors and injection site hemorrhage helps guide prescriber education and patient monitoring, while the paradoxical finding of increased appetite in some patients challenges assumptions about the drug's mechanism.

The numbers in context

1,904,481 case reports · Q2 2022 to Q3 2023 · 46 adverse drug reactions identified · 8 system organ classes · 4 statistical methods used (ROR, PRR, BCPNN, EBGM)

How the study worked

The researchers extracted tirzepatide-associated adverse event reports from the FDA Adverse Event Reporting System (FAERS) database covering Q2 2022 through Q3 2023. They used four established disproportionality analysis methods — reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM) — to detect statistically significant safety signals. Results were classified using the MedDRA (Medical Dictionary for Regulatory Activities) coding system.

Who was studied

Real-world adverse event reports from tirzepatide users in the FDA FAERS database (2022-2023)

What this study cannot tell us

FAERS is a voluntary reporting system subject to reporting bias — adverse events may be over- or under-reported, and reports do not prove causation. The database cannot establish incidence rates since the total number of patients using the drug is unknown. Reports may contain duplicates, incomplete information, or confounding factors from co-medications. The analysis period covers only the first ~18 months after approval when reporting rates tend to be higher.

How to read the evidence

This is rated Moderate because FAERS analysis is a standard pharmacovigilance method using a large dataset, but it relies on voluntary reporting and cannot establish causation or incidence rates. The use of four statistical methods strengthens signal detection reliability.

When this study was published

Published in 2024 covering data from 2022-2023, this is among the first comprehensive FAERS analyses of tirzepatide. As more patients use the drug for longer periods, additional safety data will continue to accumulate.

The bigger picture

As GLP-1/GIP agonists like tirzepatide are prescribed to millions of people, post-marketing surveillance becomes critical for identifying safety signals that clinical trials — with their controlled conditions and selected populations — might miss. This type of pharmacovigilance study is a standard tool in drug safety monitoring and has historically led to label changes, black box warnings, and in rare cases, drug withdrawals. For tirzepatide, the findings are largely reassuring but highlight areas needing attention, particularly around patient education on proper dosing and injection technique.

Questions still open

Why do some tirzepatide patients paradoxically experience increased appetite, and is this related to dose, duration, or individual biology?
How do tirzepatide's real-world adverse event patterns compare to those of semaglutide in the same database?
Will longer-term FAERS analysis reveal additional safety signals as the drug reaches more patients and longer treatment durations?

Common questions

What unexpected side effects did this study find for tirzepatide?

Beyond the expected gastrointestinal effects (acid reflux, indigestion, vomiting), the analysis flagged three unexpected signals: dosing errors (patients taking the wrong amount), injection site hemorrhage (bleeding at the injection site), and paradoxically increased appetite in some patients — the opposite of tirzepatide's intended appetite-suppressing effect.

Does this study mean tirzepatide is unsafe?

No. Most identified adverse events were already known and listed on the drug's label. The unexpected signals were generally not severe. FAERS analysis identifies potential safety signals that warrant monitoring — it doesn't prove that these events were caused by the drug or that they occur commonly. The findings are meant to improve safe use, not to alarm patients.

Read the original research

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.

Frontiers in pharmacology, 15, 1397029

View on PubMed ↗Publisher’s paper ↗

Citation

Liu, Liyuan. (2024). A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.. Frontiers in pharmacology, 15, 1397029. https://doi.org/10.3389/fphar.2024.1397029